



What is Claimed is:


1. A compound selected from the group consisting of



,



,



,



,



,



,


,


,



,


, and



,

and hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof.


2. The compound according to claim 1, wherein the compound is


.


3. The compound according to claim 1, wherein the compound is


.


4. The compound according to claim 1, wherein the compound is




5. The compound according to claim 1, wherein the compound is




6. The compound according to claim 1, wherein the compound is




7. The compound according to claim 1, wherein the compound is




8. The compound according to claim 1, wherein the compound is




9. The compound according to claim 1, wherein the compound is




10. The compound according to claim 1, wherein the compound is



11. The compound according to claim 1, wherein the compound is



12. The compound according to claim 1, wherein the compound is




13. A composition comprising a compound according to any of claims 1 to 11 and a pharmaceutically acceptable carrier.


14. Use of a compound according to any of claims 1 to 12 or a composition thereof in the manufacture of a medicament for the treatment of an opthalmic disease, wherein the ophthalmic disease, disorder or condition is selected from the group consisting of (a) a disease, disorder or condition caused by choroidal angiogenesis, (b) diabetic retinopathy and (c) retinal edema.


15. The use of a compound according to claim 14, wherein the ophthalmic disease, disorder condition is age-related macular degeneration.


What is claimed is:


1. A compound selected from the group consisting of



















and pharmaceutically acceptable salts, racemic and scalemic mixtures, diastereomers and enantiomers thereof.


2. The compound according to claim 1, wherein the compound is




3. The compound according to claim 1, wherein the compound is




4. The compound according to claim 1, wherein the compound is




5. The compound according to claim 1, wherein the compound is




6. The compound according to claim 1, wherein the compound is




7. The compound according to claim 1, wherein the compound is




8. The compound according to claim 1, wherein the compound is




9. The compound according to claim 1, wherein the compound is




10. The compound according to claim 1, wherein the compound is



11. The compound according to claim 1, wherein the compound is



12. The compound according to claim 1, wherein the compound is



13. A composition comprising a compound according to any of claims 1 to 11 and a pharmaceutically acceptable carrier.